Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer

Table 2 Log-rank analysis of TTP and OS in the 138 patients who received maintenance therapy

Variable	Median TTP (months)	P value	Median OS (months)	P value
Age (years)		0.516		0.609
≤50	10		42
>50	9		36
Menopausal status		0.306		0.076
Premenopausal	10		45
Postmenopausal	10		37
KPS score		0.916		0.039^a
70–80	8		33
90–100	8		44
DFS (years)		0.670		0.077
≤2	10		34
>2	8		43
No. of metastases		0.081		0.114
≤1	14		55
>1	9		36
Site of metastases
Viscera	9	0.106	41	0.905
Non-viscera	13		42
Response to FCCT		0.883		0.337
SD	10		41
CR + PR	10		43

TTP time-to-progression, OS overall survival, KPS Karnofsky performance status, CR complete response, PR partial response, SD stable disease, DFS disease-free survival, CT chemotherapy, FCCT first-line capecitabine-based combination chemotherapy
^aSince there were only 36 patients in the group whose KPS score was 70-80, no conclusions could be drawn from the log-rank analysis of OS

ISSN: 2523-3548